大剂量免疫抑制并自体外周血CD34～+细胞移植治疗重症/难治性自身免疫病的临床研究
|
摘要
目的：
探讨大剂量免疫抑制治疗(HDIT)并自体外周血CD34+细胞移植治疗重症系统性红斑狼疮(SLE)和难治性类风湿关节炎(RA)的可行性、疗效及安全性。
方法：
自1999年起，对10例长期应用激素和免疫抑制剂不能缓解病情的重症SLE和1例应用4种以上慢作用抗风湿药物(DMARDs)不能控制病情活动的难治性RA患者进行大剂量免疫抑制并CD34+细胞移植(HSCT)治疗。入选病例均无严重的不可逆性内脏功能受损，无严重的药物过敏史，并于治疗前签署知情同意书。
1．HDIT+HSCT方案实施步骤：
1．1．患者状况评估：对入组的SLE患者的疾病活动程度行SLE-DAI评分，对RA患者的疾病活动程度行DAS28评分，并评估各脏器功能，同时排除结核、病毒等活动性感染。
1．2．干细胞动员、采集和分选：用环磷酰胺(CY)2g／m~2和粒细胞集落刺激因子(G-CSF)5ug·kg~(-1)·d~(-1)行干细胞动员，动员成功后用血细胞分离机采集外周血单个核细胞(其中富含CD34+细胞)。应用ClinMACS细胞分选仪进行CD34+细胞分选。经处理完毕的采集物深低温冻存以备回输。
1．3．预处理方案：包括两种标准预处理方案，根据患者的具体情况选用：
一为CY+抗胸腺免疫球蛋白(ATG)：CY 200mg／kg，ATG 90mg／kg；
二是CY+全身照射(TBI)：CY200mg／kg，TBI 4 Gy。
1．4．造血干细胞回输：将造血干细胞于37℃水浴中快速复温，10～30分种内快速回输。
2．造血重建和免疫重建监测：造血重建定义为中性粒细胞连续3天＞1×10~9／L，血小板计数连续3天＞20×10~9／L。移植后每3个月应用流式细胞仪检测外周血淋巴细胞表型，以监测移植后免疫重建过程。同时比较接受HSCT的SLE患者的淋巴细胞表型与未行移植治疗的SLE活动患者和SLE平稳患者之间淋
Objectives
To assess the feasibility, safety, and efficacy of intensive immunosuppression and autologous hemopoietic stem cell transplantation in severe systemic lupus erythematosus and refractory rheumatoid arthritis.
Methods
Ten patients with severe and persistent SLE despite use of prednisone and immunosupression agents and one patient with active, destructive, refractory RA entered the study. The eligible patients were with no severe non-reversible organ function impairment, no history of severe allergy to drugs. All patients provided written informed consent.
1. Treatment protocols of HDIT+HSCT:
1.1. Mobilization and leukapheresis of peripheral stem cell and selection of CD34~+ cells: The mobilization regimen was CY 2 ~ 4 g/m~2 and G-CSF 5 μg·Kg~(-1)·d~(-1). Peripheral mononuclear cells fraction in which stem cells were enriched was collected by use of the cytocentrifuge. Then a ClinMACS was used to select CD34~+ cells.
1.2.Conditioning regimen: We applied regimens of CY+ATG or CY+TBI. Total dose is CY 200 mg/kg , ATG 90 mg/kg and TBI 4 Gy.
1.3. Infusion of CD34~+ cells: CD34~+ cells were reinfused intravenously within 10 to 30 minutes after defrostment.
2. Monitoring of hematopoietic and immune reconstitution: ANC > 1.0 × 10~9/L for consecutive 3 days, the first day of these 3 days is defined to the neutrophil recovering time. Platelet count > 20× 10~9/L for consecutive 3 days, the third day of those 3 days is defined to the platelet recovering time. Detect the phenotype of the lymphocyte in the peripheral blood every three months after transplantation to monitor the immune reconstitution process. The difference of lymphocyte
探讨大剂量免疫抑制治疗(HDIT)并自体外周血CD34+细胞移植治疗重症系统性红斑狼疮(SLE)和难治性类风湿关节炎(RA)的可行性、疗效及安全性。
方法：
自1999年起，对10例长期应用激素和免疫抑制剂不能缓解病情的重症SLE和1例应用4种以上慢作用抗风湿药物(DMARDs)不能控制病情活动的难治性RA患者进行大剂量免疫抑制并CD34+细胞移植(HSCT)治疗。入选病例均无严重的不可逆性内脏功能受损，无严重的药物过敏史，并于治疗前签署知情同意书。
1．HDIT+HSCT方案实施步骤：
1．1．患者状况评估：对入组的SLE患者的疾病活动程度行SLE-DAI评分，对RA患者的疾病活动程度行DAS28评分，并评估各脏器功能，同时排除结核、病毒等活动性感染。
1．2．干细胞动员、采集和分选：用环磷酰胺(CY)2g／m~2和粒细胞集落刺激因子(G-CSF)5ug·kg~(-1)·d~(-1)行干细胞动员，动员成功后用血细胞分离机采集外周血单个核细胞(其中富含CD34+细胞)。应用ClinMACS细胞分选仪进行CD34+细胞分选。经处理完毕的采集物深低温冻存以备回输。
1．3．预处理方案：包括两种标准预处理方案，根据患者的具体情况选用：
一为CY+抗胸腺免疫球蛋白(ATG)：CY 200mg／kg，ATG 90mg／kg；
二是CY+全身照射(TBI)：CY200mg／kg，TBI 4 Gy。
1．4．造血干细胞回输：将造血干细胞于37℃水浴中快速复温，10～30分种内快速回输。
2．造血重建和免疫重建监测：造血重建定义为中性粒细胞连续3天＞1×10~9／L，血小板计数连续3天＞20×10~9／L。移植后每3个月应用流式细胞仪检测外周血淋巴细胞表型，以监测移植后免疫重建过程。同时比较接受HSCT的SLE患者的淋巴细胞表型与未行移植治疗的SLE活动患者和SLE平稳患者之间淋
Objectives
To assess the feasibility, safety, and efficacy of intensive immunosuppression and autologous hemopoietic stem cell transplantation in severe systemic lupus erythematosus and refractory rheumatoid arthritis.
Methods
Ten patients with severe and persistent SLE despite use of prednisone and immunosupression agents and one patient with active, destructive, refractory RA entered the study. The eligible patients were with no severe non-reversible organ function impairment, no history of severe allergy to drugs. All patients provided written informed consent.
1. Treatment protocols of HDIT+HSCT:
1.1. Mobilization and leukapheresis of peripheral stem cell and selection of CD34~+ cells: The mobilization regimen was CY 2 ~ 4 g/m~2 and G-CSF 5 μg·Kg~(-1)·d~(-1). Peripheral mononuclear cells fraction in which stem cells were enriched was collected by use of the cytocentrifuge. Then a ClinMACS was used to select CD34~+ cells.
1.2.Conditioning regimen: We applied regimens of CY+ATG or CY+TBI. Total dose is CY 200 mg/kg , ATG 90 mg/kg and TBI 4 Gy.
1.3. Infusion of CD34~+ cells: CD34~+ cells were reinfused intravenously within 10 to 30 minutes after defrostment.
2. Monitoring of hematopoietic and immune reconstitution: ANC > 1.0 × 10~9/L for consecutive 3 days, the first day of these 3 days is defined to the neutrophil recovering time. Platelet count > 20× 10~9/L for consecutive 3 days, the third day of those 3 days is defined to the platelet recovering time. Detect the phenotype of the lymphocyte in the peripheral blood every three months after transplantation to monitor the immune reconstitution process. The difference of lymphocyte
引文
1. Baldwin JL, Storb R, Thomas ED, et al. bone marrow transplantation in patients with gold-induced marrow aplasia. Arthritis Rheum, 1997, 20:1043.
2. Marmont AM. van-Lint-MT. Gualandi-F. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration.Lupus. 1997, 6: 545.
3. Sullivan KM, Furst DE. The evolving role of blood and marrow transplantation for the treatment of autoimmune diseases. J Rheumatol, 1997, 48(Suppl): 1.
4. Karussis DM, Vourka-Karussis U, Lehmann D, et al. Immunomodulation of autoimmuneity in MRL/1pr mice with syngeneic bone marrow transplantation (SBMT). Clin Exp Immunol. 1995, 100: 111.
5. Gratwohl A, Hermans J, Baldomero H. Bone marrow transplant activeity in Europe 1995. Bone Marrow Transplant.1997, 19: 407.
6. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant, 1997, 19:643.
7. Tyndall A, Gratwohl A. Immuen ablateon and stem-cell therapy in autoimmune disease Clinical experience. Arthritis Res 2000,2:276-80.
8. Bombradier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI, a disease activeity index for lupus patients. Arthritis Rheum, 1992, 35: 630.
9. Prevoo ML, Van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum, 1995, 38: 44.
10. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum, 1993,36: 729.
11. Fries JF, Spitz P, Kraines RG, et al. Measuement of patient outcome in arthritis. Arthritis Rheum, 1980,23: 137.
12. Meenan RF, Gertman PM, Manson J. Measuring heaith status in arthritis, the arthritis impact measurement scales. Arthrits Rheum, 1980,23: 146.
13. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer, 1981,47: 207.
14. Adachi Y, Inaba M, Amoh Y, et al. Effect of bone marrow transplantation on antiphospholipid antibody syndrome in murine lupus mice. Immunobiology 1995; 192:218.
15. Tyndall A, Gratwohl A.Haemopoietic stem and progenitor cells in the treatment of severe AID. Ann Rheum Dis, 1996, 55: 149.
16. Burt RK, Fassas A, Snowden J, et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant, 2001, 28: 1.
17. Brodsky RA, Petri M, Smith BD. Bone marrow transplantation for autoimmune diseases. Curr Opin Oncol, 1999,11.
18. Moore J, Milliken S, David MA, et al. Peripheral blood stem cell transplantation for rheumatoid arthritis - Australian experience. The Jorunal of Rheum, 2001,28 (suppl 64): 8.
19. Traynor AE, Schroeder J, Rosa RM, et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet, 2000, 356:701.
20. Harris DT, Schumacher MJ, Ryxhlik S, et al. Collection, separation and cryopreservation of umbilical cord blood for use in transplantation. Bone Marrow Transplant, 1994,13: 135.
21.Cesana C, Carlo SC, Regazzi E, et al. CD34~+ cell mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34~+ cells mobilized by G-CSF. Bone Marrow Transplant, 1998, 21: 561.
22. Burt RK, Traynor AM, Pope R, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood, 1998, 92:3505.
23．江岷，陈虎，黄云中等．外周血CD34~+细胞的纯化及其移植后造血重建．中华血液学杂志，2001，22：432．
24. Divine M, Boutolleau D, Delfau-Larue MH, et al. Poor lymphocyte recovery following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Br J Haematol, 1999, 105:349.
25. Marmont AM, van Lint MT, Occhini D, et al. Failure of autologous stem cell transplantation in refractory thrombocytopenic purpura. Bone Marrow Transplant, 1998, 22:827.
26. Verburg RJ, Kruize AA, van den Hoogen FHJ, et al. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis. Arthritis Rheum, 2001, 44: 754.
27. van Laar JM. Immune ablation and stem cell therapy in autoimmune disease: immunological reconstitution after high-dose immunosuppression and hematopoietic stem cell transplantation. Arthritis Res, 2000, 2: 270.
28. Brodsky RA, Petri M, Smith BD, et al. Immunoablative high-dose cyclophosphamide without stem cell rescue for refractory, severe autoimmune disease. Ann Intern Med, 1998, 129:1031.
29. Nousari He, Brodsky RA, Jones RJ, et al. Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease. J Am Acad Dermatol, 1999, 40: 750.
30. Pestronk A, Drachman DB, Adams Rn, et al. Treatment of ongoing experimental myasthenia gravis with short term high dose cyclophosphamide. Muscle nerve, 1982, 5: 79.
31．曾小峰，李东兵，董怡．系统性红斑狼疮患者误服大剂量甲氨蝶呤1例． 中华内科杂志，1994，33：412．
32．王辉，于有山，李振彬．误服大剂量甲氨蝶呤2例．中华风湿病学杂志，1998，2：142．
33. Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide resistant L 1210 leukemia. Cancer Res, 1984, 44: 5156.
34. Jones RJ, Barber JP, Vala MS, et al. Assessment of aldehyde dehydrogenase in viable cells. Blood, 1995, 85: 2742.
35. Kastan MB, Schlaffer E, Russo JE, et al. Direct demonstration of elevated aldehyde dehydrogenase in human hemapoietic progenitor cells. Blood, 1990, 75:1947.
36. Bingham S, Snowden J, Mcgonagle D, et al. Autologous stem cell transplantation for rheumatoid arthritis: Interim Report of 6 patients. J Rheumatol, 2001, 28 (Suppl 64):21.
37. Van Bekkum DW. Autologous stem cell therapy for treatment of autoimmune diseases. Exp Hematol. 1998, 26:831.
38. Elhasid R, Ben Arush MW, Rowe JM, et al. Immune and hematopoietic reconstitution after transplantation of cord blood progenitor cells: case report and review of the literature. Leukemia, 2000, 14:931.
39. Rocha B, Gromdien A, Treita AA. Anergy and exhaustion are independent mechanisms of peripheral T cell tolerance .J Exp Med. 1995,181:993-1003.
40. Kook H, Goldman F, Trigg M, et al. Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children: immunophenotypic analysis and factors affecting the speed of recovery. Blood, 1996,88:1089.
41. Mackall CL, Bare CV, Gress RE, et al. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol, 1996, 15:4609.
42. Koehne G, Zeller W, Stockschlaeder M, et al. Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation. Transplant, 1997, 19,149.
43. Bingham S, Snowden J, Mcgonagle D, et al. Autologous stem cell transplantation for rheumatoid arthritis: Interim Report of 6 patients. J Rheumatol, 2001,28 (Suppl 64):21.
44. Katsura K, Nomura S, Ohtani T, et al. Changes of immunological markers after autologous peripheral blood stem cell transplantation. J Cancer Res Clin Oncol, 1998,124:633.
45. Pavletic SZ, Odell JR, Pirruccello SJ, et al. Intensive immunoablation and autologous blood cell transplantation in patients with refracrory rheumatoid arthritis: the University of Nebraska experience. J Rheumatol, 2001,28 (Suppl 64):13.
46. Bingham S, Veale D, Fearon U, et al. High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: Short-term efficacy correlates with reduction of macroscopic and histologic synovitis. Arthritis Rheum, 2002, 46:837.
1. Baldwin JL, Storb R, Thomas ED, et al. Bone marrow transplantation in patients with gold-induced marrow aplasia. Arthritis Rheum 1977, 20: 1043.
2. Jakobs P, Vincet MD, Martell RW, et al. Prolonged remission of severe refractory rheumatoid arthritis following allogeneic bone marrow transplantation for drug-induced aplastic anemia. Bone Marrow Transplant, 1986, 1: 237.
3. Lowenthal RM, Cohen ML, Atkinson K, et al. Apparent cure of rheumatoid arthritis by bone marrow transplantation. J Rheumatol, 1993, 20: 137-40.
4. McKendry R JR, Huebsch L, Lelair B. Progression of rheumatoid arthritis following bone marrow transplantation: a case report with a 13-year follow up. Arthritis Rheum, 1996, 39: 1246-53.
5. Marmont AM, van Lint MT, Gualandi F, et al. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus,1997, 6, 545.
6. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant, 1997, 19: 643.
7. Fassas A, Anagnostopoulos A, Kazis A, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results from a pilot study. Bone Marrow Transplant, 1997, 20:631.
8. Burt RK, Traynor A, Ramsey-Goldmen R, et al. Hematopoietic stem cell transplantation for systemic lupus erythematosus. N Engl J Med, 1997, 337:1777.
9. Tyndall A, Gratwohl A. Consensus statement on blood and stem cell transplantation in autoimmune diseases. Br J Rheumaol, 1997, 36: 390.
10. Traynor AE, Schroeder J, Rosa RM, et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase Ⅰ study. Lancet, 2000, 356: 701.
11. Huang S, Ferstappen WMM. Lymphoid and myeloid differentiation of single human CD34+ HLA-DR+CD38- hematopoietic stem cell. Blood, 1994, 83:1515
12. Nakahara T, Ogawa M. Identification in culture of a class of haemopoietic colonies. Proc Natl Acad Sci, 1982, 79: 3843.
13. Saito M. Recent trends in research on differentiation of hematopoietic cells and lymphokins (hemopoietins). Hum Cell, 1992, 5: 54.
14. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell, 1994, 79: 241.
15. Miraglia S, Godfrey W, Yin Ah, et al. a novel five-transmenbrane hematopoietic stem cell antigen: isolation, characterization and molecular cloning. Blood, 1997,90:5013.
16. Yin HA, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem cell progenitor cells. Blood, 1997, 90: 5002.
17. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow in cells. Radiat Res, 1961, 14: 213.
18．裴雪涛，吴祖泽，Coutinho LH，等．单个CD34+CD38+和CD34+CD38-细胞增殖与分化性能．中华血液杂志，1995，16：625．
19. Huang S, Terstappen LWMH. Formation of both hematopoietic microenvironment and hematopoietic stem cells from single human marrow stem cells. Nature, 1992, 360: 967.
20．文耕云，裴雪涛，吴祖泽．CD34的分子生物学研究进展．实验血液学杂志，1995，3：250．
21. He XX, Anto VP, Basila D, et al. Isolation and molecular characterization of the human CD34 gene. Blood, 1992, 79: 2296.
22. He XX, Cockerill PN, Cen DZ, et al. Transcriptional regulation and chromatin structure of the human CD34 gene promoter region. Blood, 1994, 83:1822.
23．裴雪涛，王立生，徐黎，等．造血干细胞/祖细胞分离纯化与体外扩增．实验血液杂志，1996，4：6．
24. Simmons DL, Satterhwaite AB, Tenen DG, et al. Molecular cloning of a cDNA encoding CD34, a sialomucin of human hematopoietic stem cells. J Immunol, 1992,148:267.
25．裴雪涛，吴祖泽，Coutinho LH，等．利用吸附单克隆抗体-磁珠分离系统分离CD34+造血干细胞．中华血液学杂志，1995，16：270．
26. de Wynter EA, Countinho LH, Pei XT, et al. Comparison of purity and enrichment of CD34+ cells from bone marrow, umbilical cord and peripheral blood (primed for apheresis) using five separation system. Stem Cells, 1995, 13: 524.
27. Kato K, Radbruch A. Isolation and characterization of CD34+ hematopoietic stem cells from human peripheral blood by highgrandient magnetic cell sorting. Cytometry, 1993, 14: 384.
28. Pei XT, Wu CT, Coutinho LH, et al. Human primitive hematopoietic progenitor cells are more enriched in CD34+CD38- population than in CD34+CD38+ population. J Exp Hematol, 1995, 3:152.
29．裴雪涛，吴祖泽，Coutinho LH，等．单个CD34+CD38+和CD34+CD38-细胞的增殖与分化性能．中华血液学杂志，1995，16：625．
30. Brugger W, Mocklin W, Heimfeld S, et al. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, IL-1β, IL-6, IL-3, interferon-γ, and erythropoietin. Blood, 1993, 81: 2597.
31．裴雪涛，王力生，徐黎，等．造血生长因子对脐带血CD34+细胞的体外扩增作用．中华血液杂志，1996，17：305．
32. Alcorn MJ, Holyoake TL, Richmond LJ, et al. Improved ex vivo expansion of CD34 selected PBPC using high expansion culture bags. Br J Haematol, 1996, 93 (suppl 1): 42a
33. Rusten Ls, Lyman SD, Veiby OP, et al. The FLT-3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro. Blood, 1996, 87:1317.
34. Petzer AL, Hogge DE, Lansdrop PM, et al. Self-renewal of primitive human hematopoietic cells (long-term culture-initiating cells) in vitro and their expansion in defined medium. Proc Natl Acad Sci USA, 1996, 93: 1470.
35. Shah AJ, Smogorezewska EM, Hannum C, et al. Flt3 ligand (FL) is a potentinducer of proliferation of highly quiescent human bone marrow CD34+CD38-cells. Blood, 1995, 86 (Suppl 1):432a
36. Mayani H, Little MT, Dragowska W, et al. Differential effects of thehematopoietic inhibitors MIP-1α, TGF-β, and TNF-α on cytokine-inducedproliferation of subpopulations of CD34+ cells purified from cord blood and fetalliver. Exp Hematol, 1995, 23: 332.
37. Gupta P, McCarthy JB, Verfaillie CM. Stromal fibroblast heparan sulfate isrequired for cytokine-mediated ex vivo maintenance of human long-termculture-initiating cells. Blood, 1996, 87: 3229.
38. Koller MR, Emerson SG, Palsson BO, et al. Large-scale expansion of humanstem and progenitor cells from bone marrow mononuclear cells in continuous perfusion culture. Blood, 1993, 82: 378.
39. Laiuppa JA, Papoutsakis ET, Miller WM, et al. Evaluation of cytokines for expansion of the megakarocyte and granulocyte lineages. Stem Cells, 1997, 15:198.
40. Pierelli L, Scambia G, Menichella G, et al. Purified unfractionated G-CSF/chemotherapy mobilized CD34+ peripheral blood progenitors and not bone marrow CD34+ progenitors undergo selective erythroid differentiation in liquid culture in the presence of erythropoietin and stem cell factor. Br J Haematol, 1997, 96: 55.
41．裴雪涛，王立生，徐黎，等．血小板生成素对CD34+造血细胞的协同扩增作用．实验血液学杂志，1997，5：229．
42. Rosenzwajg M, Canque B, Gluckman JC, et al. Human dendritic cells differentiation pathway from CD34+hematopoietic precursor cells. Blood, 1996,87: 535.
43. Mrozek E, Anderson P, Caligiuri MA, et al. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood, 1996, 87: 2632.
44. Rosenzwajg M, mark DF, Zhu H, et al. In vivo T lymphopoiesis of human and rhesus CD34+ progenitor cells. Blood, 1996, 87: 4040.
45. Ryan DH, Nuccie BL, Ritterman I, et al. Expression of interleukin-7 receptor by lineage-negative human bone marrow progenitor with enhanced lymphoid proliferative potential and B-lineage differentiation capacity. Blood, 1997, 89: 929.
46. Arseniev L, Link H, Hubner G, et al. Transient increase of leukocytes after transplantation of expanded and nonexpanded allogeneie CD34+ blood cells is of host origin. Blood, 1997, 89: 1116.
47. Mahon FX, Lagarde VP, Chahine H, et al. Ex vivo cytokine expansion of peripheral blood 5-fluorouracil-treated CD34-positive chronic myeloid leukemia cells increase the selection of Ph negative cells. Br J Haematol, 1997, 98: 467.
48. Levine JE, Wiley J, Kletzel, et al. Cytokine-mobilized allogeneic peripheral blood stem cell transplants in children result in rapid engraftment and a high incidence of chronic GVHD. Bone Marrow Transplant, 2000, 25: 13.
49. Harris DT, Schumacher M J, Ryxhlik S, et al. Collection, separation and cryopreservation of umbilical cord blood for use in transplantation.. Bone Marrow Transplant, 1994, 13: 135.
50. Elchalal U, Fasouliotis S J, Shtochheim D, et al. Postpartum umbilical cord blood collection for transplantation: a comparison of three methods. Am J Obstert Gynecol, 2000, 182: 227.
51. Harris DT. Cord blood transplantation: implications for graft vs. host disease and graft vs. leukemia. Blood Cells, 1994, 20: 560.
52. Kinniburgh D, Russell NH. Comparative study of CD-positive cells and subpopulations in human umbilical cord blood and bone marrow. Bone Marrow Transplant, 1993, 12: 489.
53．裴雪涛，吴祖泽，Coutinho LH，等．不同来源CD34+／CD38+和CD34+／CD38-细胞群造血性能的不均一性研究．中华血液学杂志，1996，17：16．
54. Wagner JE. Umbilical cord blood transplantation: overview of the clinical experience. Blood cells, 1994, 20: 227.
55. Efremidis AP, Koumakis G, Moraki M, et al. Peripheral blood progenitor cell transplantation with single apheresis in various malignancies. Bone Marrow Transplant, 1996, 17: 673.
56. Harada M. Allogeneic peripheral blood stem cell transplantation is coming of age. Int J Hematol, 1995, 62: 1.
57. Molineux G, Pojda Z, Hamposon IN, et al. Transplantation potential of peripheral blood stem cell induced by granulocyte colony-stimulating factor. Blood, 1990, 76: 2153.
58. Prummer O, Raghavaachar A, Theodor M, et al. Recovery of immune functions in dogs after total body irradiation and transplantation of autologus blood or bone marrow cells. Exp Hematol, 1985, 13: 891.
59. Petengell R, Testa NC. Biology of blood progenitor cells used in transplantation. Int J Hematol, 1995, 61: 1.
60．马恩普，刘秀珍，韩颖，等．低分子量硫酸葡聚糖对Beagle狗外周血动员作用的研究．中华血液学杂志，1996，17：251．
61. Cesana C, Carlo SC, Regazzi E, et al. CD34+ cell mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSE Bone Marrow Transplant, 1998, 21: 561.
62. Burt RK, Fassas A, Snowden J, et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant, 2001, 28: 1-12.
63. Brodsky RA, Petri M, Smith BD. Bone marrow transplantation for autoimmune diseases. Curr Opin Oncol, 1999, 11: 83.
64. Brodsky RA, Petri M, Smith BD. Immunoblative high-dose cyclophosphamide without stem cell rescue for refractory severe autoimmune disease. Ann Inter Med, 1998, 129: 1031.
65. Burr RK, Traynor AE, Cohen B, et al. T cell-depleted autologus hematopoietic stem cell transplantation for multiple sclerosis. Bone Marrow Transplant, 1998, 21:537.
66. Ikehara S. Bone marrow transplantation for autoimmune diseases. Acta Haematol, 1998,99:116.
67. Marmont A. Stem cell transplantation for severe autoimmune disorders, with special reference to rheumatic diseases. J Rheumatol, 1997,24: 13.
68. Snowden JA, Brooks PM, Biggs JC, et al. Haemopoietic stem cell transplantation for autoimmune diseases. Br J Haematol, 1997, 99: 9.
69. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Br J Rheumatol, 1997, 36: 390.
70. Liu-yin, Jowitt SN. Resolution of immune mediated diseases following allogeneic bone marrow transplantation for leukaemia. Bone Marrow Transplant, 1992, 9: 31.
71. Eedy DJ, Burrows D, Bridges JM, et al. Clearance of severe psoriasis after allogeneic bone marrow transplantation. BMJ, 1990, 300: 908.
72. Snowden JA, Kearney P, Kearney A, et al. Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation. Arthritis Rheum, 1998, 41:453.
73. Kishimoto Y, Yamamoto Y, Ito T, et al. Transfer of autoimmune thyroiditis and resolution of palmophantar pustular psoriasis following bone marrow transplantation. Bone Marrow Transplantation, 1997,19: 1041.
74. Roychoudhury DF, Linker CA. Pure red cell aplasia complicating an ABO-compatible allogeneic bone marrow transplantation, treated successfully with antithymocyte globulin. Bone Marrow Transplant, 1995, 16: 471.
75. Vento S, Cainelli F, Ghironzi G, et al. Resolution of autoimmune hepatitis after bone marrow transplantation. Lancet, 1996, 348: 544.
76. Brodsky RA, Petri M, Jones RJ. Hematopoietic stem cell transplantation for systemic lupus erythematosus. Rheum Dis Clin North Am, 2000,26: 377.
77. Tyndall A, Grotwohl A. Immune ablation and stem-cell therapy in autoimmune disease clinical experience. Arthritis Res, 2000, 2: 276.
78. Ikehara S. Autoimmune diseases as stem cell disorders: Normal stem cell transplantation for their treatment. Int J Mol Med, 1998, 1: 5.
79. Breban M, Dougados M, Fiecard F, et al. Intensified-dose (4 gm/m~2) cyclophosphamide and granulocyte colony=stimulating factor administration for hematopoietic stem cell mobilization in refractory rheumatoid arthritis. Arthritis Rheum, 1999, 42: 2275.
80. Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide resistant L 1210 leukemia. Cancer Res, 1984, 44: 5156.
81. Jones RJ, Barber JP, Vala MS, et al. Assessment of aldehyde dehydrogenase in viable ceils. Blood, 1995, 85: 2742.
82. Kastan MB, Schlaffer E, Russo JE, et al. Direct demonstration of elevated aldehyde dehydrogenase in human hemapoietic progenitor ceils. Blood, 1990, 75: 1947.
83. Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in sever aplastic anemia after high-dose cyclophospharnide without bone marrow transplantation. Blood, 1996, 87: 491.
84. Brodsky RA, Fetri M, Smith Douglas, et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann intern Med, 1998, 129: 1031.
85. Nousari Hc, Brodsky RA, Jones RJ, et al. Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease. J Am Acad Dermatol, 1999, 40: 750.
86. Champlin R, Khouri I, Komblau S, et al. Nonmyeloablative preparative regimes and induction of graft-vs-malignacy effect. Oncology, 1999, 13: 621.
87. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 1998, 91: 756.
88. Carells AM, Champlin R, Slavin S, et al. Miniallografts: ongoing trials in human. Bone Marrow Transplant, 2000, 25: 345.
89. McSweeney PA, Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Bone Marrow Transplant, 1999, 5: 192.
90. Watanabe-Fukunaga R, Brarman CI, Copeland NG, et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. nature, 1992, 356: 314.
91. Pestronk A, Drachman DB, Adams RN, et al. Treatment of ongoing experimental myasthenia gravis with short term high dose cyclophosphamide. Muscle Nerve, 1983, 5: 79.
92. Pestronk A, Drachman DB, Teoh R, et al. Combined short-term immunotherapy for experimental autoimmune myasthenia gravis. Ann Neurol, 1983, 14: 235.
93. Horowitz MM, Rowlings PA. An from the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry on current activity in hematopoietic stem cell transplantation. Curr Opin Hematol, 1997, 395: 4.
94. Adachi Y, Inhaba M, Amoh Y, et al. Effect of bone marrow transplantation on antiphospholipid antibody syndrome in murine lupus mice. Immunobiology, 1995, 218: 192.
95. McAllister LD, Beatty PG, Rose J. Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis. Bone Marrow Transplant, 1997, 19: 395.
96. Meloni G, Capria S, Vignetti m, et al. Blast crisis of chronic myelogenous leukemia in long-lasting systemic lupus erythematosus: Regression of both diseases after autologous bone marrow transplantation. Blood, 1997, 89: 4659.
97. Lopez-Cubero SO, Sullivan KM, McDonald GB. Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology, 1998, 14: 433.
98. Butt RK, Traynor AE, Pope R, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood, 1998, 92: 2505.
99. Musso M, Porretto F, Crescimanno A, et al. Autologous peripheral blood stem and progenitor(CD34~+) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome, Lupus, 1998, 7, 492.
100. Verburg RJ, Kruize AA, van den Hoogen FHJ, et al. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy. Arthritis Rheum, 2001, 44: 754.
101. Guillaume T, Rubinstein DB, Symann M. Immune reconstruction and immunotherpy after autologous hematopoietic stem cell transplatation. Blood, 1998, 92: 147.
102. van Laar JM. Immune ablation and stem cell therapy in autoimmune disease: Immunological reconstruction after high-dose immunosuppression and haematopoietic stem cell transplantation. Arthritis Res, 2000, 2: 270.
103. Small TN, Keever CA, Weiner-Fedus S, et al. B-cell differentiation following autologus, conventional, or T-call depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny. Blood, 1990, 79: 1647.
104. Velardi A, Cucciaioni S, Terenzi A, et al. Acquisition of 19 isotype diversity after bone marrow transplantation in adults. J Immunol, 1998, 141: 815.
105. Lum LG. The kinetics of immune reconstruction aider human bone marrow transplantation. Blood, 1987, 69: 368.
106. Roberts MM, To LB, Teranzi, et al. Immune reconstruction following peripheral blood stem cell transplantation, autologus bone marrow transplantation and allogeneic bone man'ow transplantation. Bone Marrow Transplant, 1993, 12: 469.
107. Tyndall A, Fassas A, Passweg J, et al. Autologous haematopoietic stem cell transplants for autoimmune disease: feasibility and transplant related mortality. Bone Marrow transplant, 1999, 24: 729.
108. Gratwohl A, Tyndall A. From autoimmunity to stem cell transplantation. Crit Rev Oncol Hematol, 1999, 30: 159.
2. Marmont AM. van-Lint-MT. Gualandi-F. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration.Lupus. 1997, 6: 545.
3. Sullivan KM, Furst DE. The evolving role of blood and marrow transplantation for the treatment of autoimmune diseases. J Rheumatol, 1997, 48(Suppl): 1.
4. Karussis DM, Vourka-Karussis U, Lehmann D, et al. Immunomodulation of autoimmuneity in MRL/1pr mice with syngeneic bone marrow transplantation (SBMT). Clin Exp Immunol. 1995, 100: 111.
5. Gratwohl A, Hermans J, Baldomero H. Bone marrow transplant activeity in Europe 1995. Bone Marrow Transplant.1997, 19: 407.
6. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant, 1997, 19:643.
7. Tyndall A, Gratwohl A. Immuen ablateon and stem-cell therapy in autoimmune disease Clinical experience. Arthritis Res 2000,2:276-80.
8. Bombradier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI, a disease activeity index for lupus patients. Arthritis Rheum, 1992, 35: 630.
9. Prevoo ML, Van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum, 1995, 38: 44.
10. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum, 1993,36: 729.
11. Fries JF, Spitz P, Kraines RG, et al. Measuement of patient outcome in arthritis. Arthritis Rheum, 1980,23: 137.
12. Meenan RF, Gertman PM, Manson J. Measuring heaith status in arthritis, the arthritis impact measurement scales. Arthrits Rheum, 1980,23: 146.
13. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer, 1981,47: 207.
14. Adachi Y, Inaba M, Amoh Y, et al. Effect of bone marrow transplantation on antiphospholipid antibody syndrome in murine lupus mice. Immunobiology 1995; 192:218.
15. Tyndall A, Gratwohl A.Haemopoietic stem and progenitor cells in the treatment of severe AID. Ann Rheum Dis, 1996, 55: 149.
16. Burt RK, Fassas A, Snowden J, et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant, 2001, 28: 1.
17. Brodsky RA, Petri M, Smith BD. Bone marrow transplantation for autoimmune diseases. Curr Opin Oncol, 1999,11.
18. Moore J, Milliken S, David MA, et al. Peripheral blood stem cell transplantation for rheumatoid arthritis - Australian experience. The Jorunal of Rheum, 2001,28 (suppl 64): 8.
19. Traynor AE, Schroeder J, Rosa RM, et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet, 2000, 356:701.
20. Harris DT, Schumacher MJ, Ryxhlik S, et al. Collection, separation and cryopreservation of umbilical cord blood for use in transplantation. Bone Marrow Transplant, 1994,13: 135.
21.Cesana C, Carlo SC, Regazzi E, et al. CD34~+ cell mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34~+ cells mobilized by G-CSF. Bone Marrow Transplant, 1998, 21: 561.
22. Burt RK, Traynor AM, Pope R, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood, 1998, 92:3505.
23．江岷，陈虎，黄云中等．外周血CD34~+细胞的纯化及其移植后造血重建．中华血液学杂志，2001，22：432．
24. Divine M, Boutolleau D, Delfau-Larue MH, et al. Poor lymphocyte recovery following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Br J Haematol, 1999, 105:349.
25. Marmont AM, van Lint MT, Occhini D, et al. Failure of autologous stem cell transplantation in refractory thrombocytopenic purpura. Bone Marrow Transplant, 1998, 22:827.
26. Verburg RJ, Kruize AA, van den Hoogen FHJ, et al. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis. Arthritis Rheum, 2001, 44: 754.
27. van Laar JM. Immune ablation and stem cell therapy in autoimmune disease: immunological reconstitution after high-dose immunosuppression and hematopoietic stem cell transplantation. Arthritis Res, 2000, 2: 270.
28. Brodsky RA, Petri M, Smith BD, et al. Immunoablative high-dose cyclophosphamide without stem cell rescue for refractory, severe autoimmune disease. Ann Intern Med, 1998, 129:1031.
29. Nousari He, Brodsky RA, Jones RJ, et al. Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease. J Am Acad Dermatol, 1999, 40: 750.
30. Pestronk A, Drachman DB, Adams Rn, et al. Treatment of ongoing experimental myasthenia gravis with short term high dose cyclophosphamide. Muscle nerve, 1982, 5: 79.
31．曾小峰，李东兵，董怡．系统性红斑狼疮患者误服大剂量甲氨蝶呤1例． 中华内科杂志，1994，33：412．
32．王辉，于有山，李振彬．误服大剂量甲氨蝶呤2例．中华风湿病学杂志，1998，2：142．
33. Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide resistant L 1210 leukemia. Cancer Res, 1984, 44: 5156.
34. Jones RJ, Barber JP, Vala MS, et al. Assessment of aldehyde dehydrogenase in viable cells. Blood, 1995, 85: 2742.
35. Kastan MB, Schlaffer E, Russo JE, et al. Direct demonstration of elevated aldehyde dehydrogenase in human hemapoietic progenitor cells. Blood, 1990, 75:1947.
36. Bingham S, Snowden J, Mcgonagle D, et al. Autologous stem cell transplantation for rheumatoid arthritis: Interim Report of 6 patients. J Rheumatol, 2001, 28 (Suppl 64):21.
37. Van Bekkum DW. Autologous stem cell therapy for treatment of autoimmune diseases. Exp Hematol. 1998, 26:831.
38. Elhasid R, Ben Arush MW, Rowe JM, et al. Immune and hematopoietic reconstitution after transplantation of cord blood progenitor cells: case report and review of the literature. Leukemia, 2000, 14:931.
39. Rocha B, Gromdien A, Treita AA. Anergy and exhaustion are independent mechanisms of peripheral T cell tolerance .J Exp Med. 1995,181:993-1003.
40. Kook H, Goldman F, Trigg M, et al. Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children: immunophenotypic analysis and factors affecting the speed of recovery. Blood, 1996,88:1089.
41. Mackall CL, Bare CV, Gress RE, et al. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol, 1996, 15:4609.
42. Koehne G, Zeller W, Stockschlaeder M, et al. Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation. Transplant, 1997, 19,149.
43. Bingham S, Snowden J, Mcgonagle D, et al. Autologous stem cell transplantation for rheumatoid arthritis: Interim Report of 6 patients. J Rheumatol, 2001,28 (Suppl 64):21.
44. Katsura K, Nomura S, Ohtani T, et al. Changes of immunological markers after autologous peripheral blood stem cell transplantation. J Cancer Res Clin Oncol, 1998,124:633.
45. Pavletic SZ, Odell JR, Pirruccello SJ, et al. Intensive immunoablation and autologous blood cell transplantation in patients with refracrory rheumatoid arthritis: the University of Nebraska experience. J Rheumatol, 2001,28 (Suppl 64):13.
46. Bingham S, Veale D, Fearon U, et al. High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: Short-term efficacy correlates with reduction of macroscopic and histologic synovitis. Arthritis Rheum, 2002, 46:837.
1. Baldwin JL, Storb R, Thomas ED, et al. Bone marrow transplantation in patients with gold-induced marrow aplasia. Arthritis Rheum 1977, 20: 1043.
2. Jakobs P, Vincet MD, Martell RW, et al. Prolonged remission of severe refractory rheumatoid arthritis following allogeneic bone marrow transplantation for drug-induced aplastic anemia. Bone Marrow Transplant, 1986, 1: 237.
3. Lowenthal RM, Cohen ML, Atkinson K, et al. Apparent cure of rheumatoid arthritis by bone marrow transplantation. J Rheumatol, 1993, 20: 137-40.
4. McKendry R JR, Huebsch L, Lelair B. Progression of rheumatoid arthritis following bone marrow transplantation: a case report with a 13-year follow up. Arthritis Rheum, 1996, 39: 1246-53.
5. Marmont AM, van Lint MT, Gualandi F, et al. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus,1997, 6, 545.
6. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant, 1997, 19: 643.
7. Fassas A, Anagnostopoulos A, Kazis A, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results from a pilot study. Bone Marrow Transplant, 1997, 20:631.
8. Burt RK, Traynor A, Ramsey-Goldmen R, et al. Hematopoietic stem cell transplantation for systemic lupus erythematosus. N Engl J Med, 1997, 337:1777.
9. Tyndall A, Gratwohl A. Consensus statement on blood and stem cell transplantation in autoimmune diseases. Br J Rheumaol, 1997, 36: 390.
10. Traynor AE, Schroeder J, Rosa RM, et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase Ⅰ study. Lancet, 2000, 356: 701.
11. Huang S, Ferstappen WMM. Lymphoid and myeloid differentiation of single human CD34+ HLA-DR+CD38- hematopoietic stem cell. Blood, 1994, 83:1515
12. Nakahara T, Ogawa M. Identification in culture of a class of haemopoietic colonies. Proc Natl Acad Sci, 1982, 79: 3843.
13. Saito M. Recent trends in research on differentiation of hematopoietic cells and lymphokins (hemopoietins). Hum Cell, 1992, 5: 54.
14. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell, 1994, 79: 241.
15. Miraglia S, Godfrey W, Yin Ah, et al. a novel five-transmenbrane hematopoietic stem cell antigen: isolation, characterization and molecular cloning. Blood, 1997,90:5013.
16. Yin HA, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem cell progenitor cells. Blood, 1997, 90: 5002.
17. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow in cells. Radiat Res, 1961, 14: 213.
18．裴雪涛，吴祖泽，Coutinho LH，等．单个CD34+CD38+和CD34+CD38-细胞增殖与分化性能．中华血液杂志，1995，16：625．
19. Huang S, Terstappen LWMH. Formation of both hematopoietic microenvironment and hematopoietic stem cells from single human marrow stem cells. Nature, 1992, 360: 967.
20．文耕云，裴雪涛，吴祖泽．CD34的分子生物学研究进展．实验血液学杂志，1995，3：250．
21. He XX, Anto VP, Basila D, et al. Isolation and molecular characterization of the human CD34 gene. Blood, 1992, 79: 2296.
22. He XX, Cockerill PN, Cen DZ, et al. Transcriptional regulation and chromatin structure of the human CD34 gene promoter region. Blood, 1994, 83:1822.
23．裴雪涛，王立生，徐黎，等．造血干细胞/祖细胞分离纯化与体外扩增．实验血液杂志，1996，4：6．
24. Simmons DL, Satterhwaite AB, Tenen DG, et al. Molecular cloning of a cDNA encoding CD34, a sialomucin of human hematopoietic stem cells. J Immunol, 1992,148:267.
25．裴雪涛，吴祖泽，Coutinho LH，等．利用吸附单克隆抗体-磁珠分离系统分离CD34+造血干细胞．中华血液学杂志，1995，16：270．
26. de Wynter EA, Countinho LH, Pei XT, et al. Comparison of purity and enrichment of CD34+ cells from bone marrow, umbilical cord and peripheral blood (primed for apheresis) using five separation system. Stem Cells, 1995, 13: 524.
27. Kato K, Radbruch A. Isolation and characterization of CD34+ hematopoietic stem cells from human peripheral blood by highgrandient magnetic cell sorting. Cytometry, 1993, 14: 384.
28. Pei XT, Wu CT, Coutinho LH, et al. Human primitive hematopoietic progenitor cells are more enriched in CD34+CD38- population than in CD34+CD38+ population. J Exp Hematol, 1995, 3:152.
29．裴雪涛，吴祖泽，Coutinho LH，等．单个CD34+CD38+和CD34+CD38-细胞的增殖与分化性能．中华血液学杂志，1995，16：625．
30. Brugger W, Mocklin W, Heimfeld S, et al. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, IL-1β, IL-6, IL-3, interferon-γ, and erythropoietin. Blood, 1993, 81: 2597.
31．裴雪涛，王力生，徐黎，等．造血生长因子对脐带血CD34+细胞的体外扩增作用．中华血液杂志，1996，17：305．
32. Alcorn MJ, Holyoake TL, Richmond LJ, et al. Improved ex vivo expansion of CD34 selected PBPC using high expansion culture bags. Br J Haematol, 1996, 93 (suppl 1): 42a
33. Rusten Ls, Lyman SD, Veiby OP, et al. The FLT-3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro. Blood, 1996, 87:1317.
34. Petzer AL, Hogge DE, Lansdrop PM, et al. Self-renewal of primitive human hematopoietic cells (long-term culture-initiating cells) in vitro and their expansion in defined medium. Proc Natl Acad Sci USA, 1996, 93: 1470.
35. Shah AJ, Smogorezewska EM, Hannum C, et al. Flt3 ligand (FL) is a potentinducer of proliferation of highly quiescent human bone marrow CD34+CD38-cells. Blood, 1995, 86 (Suppl 1):432a
36. Mayani H, Little MT, Dragowska W, et al. Differential effects of thehematopoietic inhibitors MIP-1α, TGF-β, and TNF-α on cytokine-inducedproliferation of subpopulations of CD34+ cells purified from cord blood and fetalliver. Exp Hematol, 1995, 23: 332.
37. Gupta P, McCarthy JB, Verfaillie CM. Stromal fibroblast heparan sulfate isrequired for cytokine-mediated ex vivo maintenance of human long-termculture-initiating cells. Blood, 1996, 87: 3229.
38. Koller MR, Emerson SG, Palsson BO, et al. Large-scale expansion of humanstem and progenitor cells from bone marrow mononuclear cells in continuous perfusion culture. Blood, 1993, 82: 378.
39. Laiuppa JA, Papoutsakis ET, Miller WM, et al. Evaluation of cytokines for expansion of the megakarocyte and granulocyte lineages. Stem Cells, 1997, 15:198.
40. Pierelli L, Scambia G, Menichella G, et al. Purified unfractionated G-CSF/chemotherapy mobilized CD34+ peripheral blood progenitors and not bone marrow CD34+ progenitors undergo selective erythroid differentiation in liquid culture in the presence of erythropoietin and stem cell factor. Br J Haematol, 1997, 96: 55.
41．裴雪涛，王立生，徐黎，等．血小板生成素对CD34+造血细胞的协同扩增作用．实验血液学杂志，1997，5：229．
42. Rosenzwajg M, Canque B, Gluckman JC, et al. Human dendritic cells differentiation pathway from CD34+hematopoietic precursor cells. Blood, 1996,87: 535.
43. Mrozek E, Anderson P, Caligiuri MA, et al. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood, 1996, 87: 2632.
44. Rosenzwajg M, mark DF, Zhu H, et al. In vivo T lymphopoiesis of human and rhesus CD34+ progenitor cells. Blood, 1996, 87: 4040.
45. Ryan DH, Nuccie BL, Ritterman I, et al. Expression of interleukin-7 receptor by lineage-negative human bone marrow progenitor with enhanced lymphoid proliferative potential and B-lineage differentiation capacity. Blood, 1997, 89: 929.
46. Arseniev L, Link H, Hubner G, et al. Transient increase of leukocytes after transplantation of expanded and nonexpanded allogeneie CD34+ blood cells is of host origin. Blood, 1997, 89: 1116.
47. Mahon FX, Lagarde VP, Chahine H, et al. Ex vivo cytokine expansion of peripheral blood 5-fluorouracil-treated CD34-positive chronic myeloid leukemia cells increase the selection of Ph negative cells. Br J Haematol, 1997, 98: 467.
48. Levine JE, Wiley J, Kletzel, et al. Cytokine-mobilized allogeneic peripheral blood stem cell transplants in children result in rapid engraftment and a high incidence of chronic GVHD. Bone Marrow Transplant, 2000, 25: 13.
49. Harris DT, Schumacher M J, Ryxhlik S, et al. Collection, separation and cryopreservation of umbilical cord blood for use in transplantation.. Bone Marrow Transplant, 1994, 13: 135.
50. Elchalal U, Fasouliotis S J, Shtochheim D, et al. Postpartum umbilical cord blood collection for transplantation: a comparison of three methods. Am J Obstert Gynecol, 2000, 182: 227.
51. Harris DT. Cord blood transplantation: implications for graft vs. host disease and graft vs. leukemia. Blood Cells, 1994, 20: 560.
52. Kinniburgh D, Russell NH. Comparative study of CD-positive cells and subpopulations in human umbilical cord blood and bone marrow. Bone Marrow Transplant, 1993, 12: 489.
53．裴雪涛，吴祖泽，Coutinho LH，等．不同来源CD34+／CD38+和CD34+／CD38-细胞群造血性能的不均一性研究．中华血液学杂志，1996，17：16．
54. Wagner JE. Umbilical cord blood transplantation: overview of the clinical experience. Blood cells, 1994, 20: 227.
55. Efremidis AP, Koumakis G, Moraki M, et al. Peripheral blood progenitor cell transplantation with single apheresis in various malignancies. Bone Marrow Transplant, 1996, 17: 673.
56. Harada M. Allogeneic peripheral blood stem cell transplantation is coming of age. Int J Hematol, 1995, 62: 1.
57. Molineux G, Pojda Z, Hamposon IN, et al. Transplantation potential of peripheral blood stem cell induced by granulocyte colony-stimulating factor. Blood, 1990, 76: 2153.
58. Prummer O, Raghavaachar A, Theodor M, et al. Recovery of immune functions in dogs after total body irradiation and transplantation of autologus blood or bone marrow cells. Exp Hematol, 1985, 13: 891.
59. Petengell R, Testa NC. Biology of blood progenitor cells used in transplantation. Int J Hematol, 1995, 61: 1.
60．马恩普，刘秀珍，韩颖，等．低分子量硫酸葡聚糖对Beagle狗外周血动员作用的研究．中华血液学杂志，1996，17：251．
61. Cesana C, Carlo SC, Regazzi E, et al. CD34+ cell mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSE Bone Marrow Transplant, 1998, 21: 561.
62. Burt RK, Fassas A, Snowden J, et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant, 2001, 28: 1-12.
63. Brodsky RA, Petri M, Smith BD. Bone marrow transplantation for autoimmune diseases. Curr Opin Oncol, 1999, 11: 83.
64. Brodsky RA, Petri M, Smith BD. Immunoblative high-dose cyclophosphamide without stem cell rescue for refractory severe autoimmune disease. Ann Inter Med, 1998, 129: 1031.
65. Burr RK, Traynor AE, Cohen B, et al. T cell-depleted autologus hematopoietic stem cell transplantation for multiple sclerosis. Bone Marrow Transplant, 1998, 21:537.
66. Ikehara S. Bone marrow transplantation for autoimmune diseases. Acta Haematol, 1998,99:116.
67. Marmont A. Stem cell transplantation for severe autoimmune disorders, with special reference to rheumatic diseases. J Rheumatol, 1997,24: 13.
68. Snowden JA, Brooks PM, Biggs JC, et al. Haemopoietic stem cell transplantation for autoimmune diseases. Br J Haematol, 1997, 99: 9.
69. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Br J Rheumatol, 1997, 36: 390.
70. Liu-yin, Jowitt SN. Resolution of immune mediated diseases following allogeneic bone marrow transplantation for leukaemia. Bone Marrow Transplant, 1992, 9: 31.
71. Eedy DJ, Burrows D, Bridges JM, et al. Clearance of severe psoriasis after allogeneic bone marrow transplantation. BMJ, 1990, 300: 908.
72. Snowden JA, Kearney P, Kearney A, et al. Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation. Arthritis Rheum, 1998, 41:453.
73. Kishimoto Y, Yamamoto Y, Ito T, et al. Transfer of autoimmune thyroiditis and resolution of palmophantar pustular psoriasis following bone marrow transplantation. Bone Marrow Transplantation, 1997,19: 1041.
74. Roychoudhury DF, Linker CA. Pure red cell aplasia complicating an ABO-compatible allogeneic bone marrow transplantation, treated successfully with antithymocyte globulin. Bone Marrow Transplant, 1995, 16: 471.
75. Vento S, Cainelli F, Ghironzi G, et al. Resolution of autoimmune hepatitis after bone marrow transplantation. Lancet, 1996, 348: 544.
76. Brodsky RA, Petri M, Jones RJ. Hematopoietic stem cell transplantation for systemic lupus erythematosus. Rheum Dis Clin North Am, 2000,26: 377.
77. Tyndall A, Grotwohl A. Immune ablation and stem-cell therapy in autoimmune disease clinical experience. Arthritis Res, 2000, 2: 276.
78. Ikehara S. Autoimmune diseases as stem cell disorders: Normal stem cell transplantation for their treatment. Int J Mol Med, 1998, 1: 5.
79. Breban M, Dougados M, Fiecard F, et al. Intensified-dose (4 gm/m~2) cyclophosphamide and granulocyte colony=stimulating factor administration for hematopoietic stem cell mobilization in refractory rheumatoid arthritis. Arthritis Rheum, 1999, 42: 2275.
80. Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide resistant L 1210 leukemia. Cancer Res, 1984, 44: 5156.
81. Jones RJ, Barber JP, Vala MS, et al. Assessment of aldehyde dehydrogenase in viable ceils. Blood, 1995, 85: 2742.
82. Kastan MB, Schlaffer E, Russo JE, et al. Direct demonstration of elevated aldehyde dehydrogenase in human hemapoietic progenitor ceils. Blood, 1990, 75: 1947.
83. Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in sever aplastic anemia after high-dose cyclophospharnide without bone marrow transplantation. Blood, 1996, 87: 491.
84. Brodsky RA, Fetri M, Smith Douglas, et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann intern Med, 1998, 129: 1031.
85. Nousari Hc, Brodsky RA, Jones RJ, et al. Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease. J Am Acad Dermatol, 1999, 40: 750.
86. Champlin R, Khouri I, Komblau S, et al. Nonmyeloablative preparative regimes and induction of graft-vs-malignacy effect. Oncology, 1999, 13: 621.
87. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 1998, 91: 756.
88. Carells AM, Champlin R, Slavin S, et al. Miniallografts: ongoing trials in human. Bone Marrow Transplant, 2000, 25: 345.
89. McSweeney PA, Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Bone Marrow Transplant, 1999, 5: 192.
90. Watanabe-Fukunaga R, Brarman CI, Copeland NG, et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. nature, 1992, 356: 314.
91. Pestronk A, Drachman DB, Adams RN, et al. Treatment of ongoing experimental myasthenia gravis with short term high dose cyclophosphamide. Muscle Nerve, 1983, 5: 79.
92. Pestronk A, Drachman DB, Teoh R, et al. Combined short-term immunotherapy for experimental autoimmune myasthenia gravis. Ann Neurol, 1983, 14: 235.
93. Horowitz MM, Rowlings PA. An from the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry on current activity in hematopoietic stem cell transplantation. Curr Opin Hematol, 1997, 395: 4.
94. Adachi Y, Inhaba M, Amoh Y, et al. Effect of bone marrow transplantation on antiphospholipid antibody syndrome in murine lupus mice. Immunobiology, 1995, 218: 192.
95. McAllister LD, Beatty PG, Rose J. Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis. Bone Marrow Transplant, 1997, 19: 395.
96. Meloni G, Capria S, Vignetti m, et al. Blast crisis of chronic myelogenous leukemia in long-lasting systemic lupus erythematosus: Regression of both diseases after autologous bone marrow transplantation. Blood, 1997, 89: 4659.
97. Lopez-Cubero SO, Sullivan KM, McDonald GB. Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology, 1998, 14: 433.
98. Butt RK, Traynor AE, Pope R, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood, 1998, 92: 2505.
99. Musso M, Porretto F, Crescimanno A, et al. Autologous peripheral blood stem and progenitor(CD34~+) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome, Lupus, 1998, 7, 492.
100. Verburg RJ, Kruize AA, van den Hoogen FHJ, et al. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy. Arthritis Rheum, 2001, 44: 754.
101. Guillaume T, Rubinstein DB, Symann M. Immune reconstruction and immunotherpy after autologous hematopoietic stem cell transplatation. Blood, 1998, 92: 147.
102. van Laar JM. Immune ablation and stem cell therapy in autoimmune disease: Immunological reconstruction after high-dose immunosuppression and haematopoietic stem cell transplantation. Arthritis Res, 2000, 2: 270.
103. Small TN, Keever CA, Weiner-Fedus S, et al. B-cell differentiation following autologus, conventional, or T-call depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny. Blood, 1990, 79: 1647.
104. Velardi A, Cucciaioni S, Terenzi A, et al. Acquisition of 19 isotype diversity after bone marrow transplantation in adults. J Immunol, 1998, 141: 815.
105. Lum LG. The kinetics of immune reconstruction aider human bone marrow transplantation. Blood, 1987, 69: 368.
106. Roberts MM, To LB, Teranzi, et al. Immune reconstruction following peripheral blood stem cell transplantation, autologus bone marrow transplantation and allogeneic bone man'ow transplantation. Bone Marrow Transplant, 1993, 12: 469.
107. Tyndall A, Fassas A, Passweg J, et al. Autologous haematopoietic stem cell transplants for autoimmune disease: feasibility and transplant related mortality. Bone Marrow transplant, 1999, 24: 729.
108. Gratwohl A, Tyndall A. From autoimmunity to stem cell transplantation. Crit Rev Oncol Hematol, 1999, 30: 159.